臨床外科75巻8号

2020年08月発行

特集 遺伝性腫瘍とゲノム医療を学ぶ

遺伝性腫瘍

遺伝性乳癌卵巣癌（HBOC）

著者： 大住省三¹²

所属機関： ¹国立病院機構四国がんセンター乳腺外科 ²国立病院機構四国がんセンター遺伝性がん診療科

ページ範囲：P.935 - P.940

文献概要

【ポイント】
◆BRACAnalysis診断システムでBRCA遺伝学的検査を行うと，予期せずHBOCであることが判明することがある．
◆がんゲノム医療を進めていく中で，稀ではなくHBOCが見つかる．
◆いかなる状況でHBOCが見つかっても，その血縁者に遺伝医療を提供する必要がある．

参考文献

1）Kuchenbaecker KB, Hopper JL, Barnes DR, et al：Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA 317：2402-2416, 2017

2）Tai YC, Domchek S, Parmigiani G, et al：Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 99：1811-1814, 2007

3）Nyberg T, Frost D, Barrowdale D, et al：Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers：A Prospective Cohort Study. Eur Urol 77：24-35, 2020

-Associated Hereditary Breast and Ovarian Cancer. GeneReviews〔https://www.ncbi.nlm.nih.gov/books/NBK1247/〕（Accessed December 31, 2019）

5）Nakamura S, Takahashi M, Tozaki M, et al：Prevalence and differentiation of hereditary breast and ovarian cancers in Japan. Breast Cancer 22：462-468, 2015

6）Zhang S, Royer R, Li S, et al：Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol 121：353-357, 2011

7）Momozawa Y, Iwasaki Y, Parsons MT, et al：Germline pathogenic variants of 11 breast cancer genes in 7,051 Japanese patients and 11,241 controls. Nat Commun 9：4083, 2018

8）ACOG Committee on Practice Bulletins：Hereditary breast and ovarian cancer syndrome. Gynecol Oncol 113：6-11, 2009

（CHARLOTTE）．Int J Gynecol Cancer 29：1043-1049, 2019

10）NCCN Clinical Practice Guidelines in Oncology. Vers 1. 2020. Genetic/Familial High-Risk Assessment：Breast, Ovarian, and Pancreatic.〔https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf〕（Accessed December 31, 2019）

11）Kuhl C, Weigel S, Schrading S, et al：Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer：the EVA trial. J Clin Oncol 28：1450-1457, 2010

12）Riedl CC, Luft N, Bernhart C, et al：Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density. J Clin Oncol 33：1128-1135, 2015

13）Warner E, Hill K, Causer P, et al：Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol 29：1664-1669, 2011

14）日本乳癌学会（編）：乳癌診療ガイドライン②疫学・診断編　2018年版．金原出版，2018

15）Phillips KA, Milne RL, Rookus MA, et al：Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol 31：3091-3099, 2013

16）Heemskerk-Gerritsen BA, Menke-Pluijmers MB, Jager A, et al：Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers：a prospective analysis. Ann Oncol 24：2029-2035, 2013

17）Heemskerk-Gerritsen BAM, Jager A, Koppert LB, et al：Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 177：723-733, 2019

18）Evans DG, Ingham SL, Baildam A, et al：Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer. Breast Cancer Res Treat 140：135-142, 2013

19）Metcalfe K, Gershman S, Ghadirian P, et al：Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations：retrospective analysis. BMJ 348：g226, 2014

20）Heemskerk-Gerritsen BA, Rookus MA, Aalfs CM, et al：Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer：a prospective analysis. Int J Cancer 136：668-677, 2015

21）日本婦人科腫瘍学会（編）卵巣がん治療ガイドライン　2015年版．金原出版，2015

22）Marchetti C, De Felice F, Palaia I, et al：Risk-reducing salpingo-oophorectomy：a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers. BMC Womens Health 14：150, 2014

23）Iodice S, Barile M, Rotmensz N, et al：Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers：a meta-analysis. Eur J Cancer 46：2275-2284, 2010

24）Valachis A, Nearchou AD, Lind P：Surgical management of breast cancer in BRCA-mutation carriers：a systematic review and meta-analysis. Breast Cancer Res Treat 144：443-455, 2014

25）NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Vers 3. 2019〔https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf〕（accessed on December 31, 2019）

26）Pierce LJ, Phillips KA, Griffith KA, et al：Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer：comparison of breast conservation and mastectomy. Breast Cancer Res Treat 121：389-398, 2010

27）Robson ME, Tung N, Conte P, et al：OlympiAD final overall survival and tolerability results：Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol 30：558-566, 2019

28）Ledermann J, Harter P, Gourley C, et al：Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer：a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 15：852-861, 2014

29）Pujade-Lauraine E, Ledermann JA, Selle F, et al：Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation（SOLO2/ENGOT-Ov21）：a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 18：1274-1284, 2017

30）Moore K, Colombo N, Scambia G, et al：Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med 379：2495-2505, 2018

-Mutated Metastatic Pancreatic Cancer. N Engl J Med 381：317-327, 2019

mutations in HER2-negative metastatic breast cancer：Global results from the BREAKOUT study. International Oral 5 2019年10月26日　福岡市　第57回日本癌治療学会学術集会

33）Meric-Bernstam F, Brusco L, Daniels M, et al：Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Ann Oncol 27：795-800, 2016